AZTA | Ticker Profile - Titan Protect

AZTA

Azenta, Inc.

Healthcare · Medical Instruments & Supplies · NMS

$22.69

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$984M

Total market value of the company

Trailing P/E

N/A

Forward P/E

34.76

Based on estimated future earnings — lower means cheaper

Rev Growth

+1.0%

Year-over-year revenue change

Profit Margin

-29.1%

How much profit the company keeps from each dollar of revenue

ROE

-6.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$28.00

+23% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Azenta, Inc.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

https://www.azenta.com

Country: United States Employees: 2,900 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.430

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0431

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.454

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-33.7%

Historical annualised return based on price data

Max Drawdown

-74.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.43

Moves slightly more than the broader market

52W High

$41.73

46% below the year high

52W Low

$15.93

42% above the year low

Avg Volume

1,160,009

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

21.3%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.41

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.58

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.83

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.12

Like current ratio but excludes inventory — stricter test

Gross Margin

44.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-10.6%

Profit from core operations before interest and tax

Free Cash Flow

$101M

Positive — the business generates more cash than it spends

Revenue (TTM)

$596M

Total revenue over the last 12 months

Net Income

$-110,890,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$33.00

Target Median

$28.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go